Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Treatment, survival, and thromboembolic outcomes of thrombotic storm in children.

Manco-Johnson MJ, Wang M, Goldenberg NA, Soep J, Gibson E, Knoll CM, Mourani PM.

J Pediatr. 2012 Oct;161(4):682-8.e1. doi: 10.1016/j.jpeds.2012.03.042. Epub 2012 May 11.

PMID:
22578585
2.

Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.

Lin H, Faraklas I, Saffle J, Cochran A.

J Trauma. 2011 Dec;71(6):1557-61. doi: 10.1097/TA.0b013e31823070f9.

PMID:
22027887
3.

Lemierre's and Lemierre's-like syndromes in children: survival and thromboembolic outcomes.

Goldenberg NA, Knapp-Clevenger R, Hays T, Manco-Johnson MJ.

Pediatrics. 2005 Oct;116(4):e543-8. Epub 2005 Sep 1.

PMID:
16147971
4.

Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.

van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Büller HR.

Thromb Haemost. 2009 Apr;101(4):762-9.

PMID:
19350123
5.

Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children.

Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ; Mountain States Regional Thrombophilia Group.

N Engl J Med. 2004 Sep 9;351(11):1081-8. Erratum in: N Engl J Med. 2005 May 19;352(20):2146.

6.

Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.

Reeves D, Liu CY.

J Oncol Pharm Pract. 2010 Mar;16(1):27-31. doi: 10.1177/1078155209104379. Epub 2009 Apr 28.

PMID:
19401307
7.

Emerging options in the treatment of venous thromboembolism.

Nutescu EA.

Am J Health Syst Pharm. 2004 Dec 1;61(23 Suppl 7):S12-7. Review.

PMID:
15597574
8.

FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events.

Ko RH, Michieli C, Lira JL, Young G.

Thromb Res. 2014 Sep;134(3):643-7. doi: 10.1016/j.thromres.2014.07.026. Epub 2014 Jul 23.

PMID:
25087891
9.

Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery.

Farias-Eisner R, Horblyuk R, Franklin M, Lunacsek OE, Happe LE.

Curr Med Res Opin. 2009 May;25(5):1081-7. doi: 10.1185/03007990902837117 .

PMID:
19298219
10.

The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.

Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P.

Ann Intern Med. 2007 Dec 4;147(11):766-74.

PMID:
18056660
11.

The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients.

Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, Bernardi E, Girolami B, Simioni P, Girolami A.

Haematologica. 1997 Jul-Aug;82(4):423-8.

12.

Assessing, preventing, and treating venous thromboembolism: evidence-based approaches.

Nutescu EA.

Am J Health Syst Pharm. 2007 Jun 1;64(11 Suppl 7):S5-13. Review.

PMID:
17519445
13.

Periprocedural anticoagulation management of patients with venous thromboembolism.

McBane RD, Wysokinski WE, Daniels PR, Litin SC, Slusser J, Hodge DO, Dowling NF, Heit JA.

Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):442-8. doi: 10.1161/ATVBAHA.109.199406. Epub 2010 Feb 5.

14.

Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin.

González-Fajardo JA, Martin-Pedrosa M, Castrodeza J, Tamames S, Vaquero-Puerta C.

J Vasc Surg. 2008 Oct;48(4):953-9. doi: 10.1016/j.jvs.2008.05.033. Epub 2008 Jul 18.

15.

Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.

Happe LE, Farrelly EM, Stanford RH, Sarnes MW.

J Thromb Thrombolysis. 2008 Oct;26(2):125-31. Epub 2007 Nov 24.

PMID:
18034323
16.

Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis.

Shorr AF, Kwong LM, Sarnes M, Happe L, Farrelly E, Mody-Patel N.

Thromb Res. 2007;121(1):17-24. Epub 2007 Apr 20.

PMID:
17449088
17.

Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.

Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY.

J Thromb Haemost. 2009 May;7(5):760-5. doi: 10.1111/j.1538-7836.2009.03326.x. Epub 2009 Feb 24.

18.

Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.

Shorr AF, Sarnes MW, Peeples PJ, Stanford RH, Happe LE, Farrelly E.

Am J Health Syst Pharm. 2007 Nov 15;64(22):2349-55.

PMID:
17989444
19.

The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.

Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, Deangelo DJ, Silverman LB.

Br J Haematol. 2011 Feb;152(4):452-9. doi: 10.1111/j.1365-2141.2010.08524.x. Epub 2011 Jan 7.

PMID:
21210774

Supplemental Content

Support Center